BioStock: Ultimovacs can look back on strong 2020

2020 was a year of key clinical advancements for Ultimovacs. In particular, the company’s already extensive development program with top candidate UV1 became even broader with two additional phase II trials. BioStock spoke with CEO Carlos de Sousa, who assumed the role of chief executive halfway through the year, to get his take on an eventful year for Ultimovacs and what he expects in 2021.

Read the full interview with Carlos de Sousa at biostock.se:

https://www.biostock.se/en/ultimovacs-can-look-back-on-strong-2020/

This is a press release from BioStock - Connecting Innovation & Capital.